In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals
about
Confounding by indication affects antimicrobial risk factors for methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisitionA phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaValidation of pulsed-field gel electrophoresis and spa typing for long-term, nationwide epidemiological surveillance studies of Staphylococcus aureus infections.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Investigational treatments for postoperative surgical site infections.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Evaluation of new Vitek 2 card and disk diffusion method for determining susceptibility of Staphylococcus aureus to oxacillin.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenoCeftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Current challenges in treating MRSA: what are the options?Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.β-lactams against emerging 'superbugs': progress and pitfalls.National surveillance of Staphylococcus epidermidis recovered from bloodstream infections in Belgian hospitals.Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.Genotypic and phenotypic characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolated from milk of bovine mastitis.Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus.Antimicrobial-resistant pathogens in animals and man: prescribing, practices and policies.Community-acquired methicillin-resistant Staphylococcus aureus clones circulating in Belgium from 2005 to 2009: changing epidemiology.Genetic diversity among methicillin-resistant Staphylococcus aureus isolates carrying the mecC gene in Belgium.Previous healthcare exposure is the main antecedent for methicillin-resistant Staphylococcus aureus carriage on hospital admission in Belgium.
P2860
Q33756510-8038ED8A-0281-43A8-9C37-DF69F22D1A17Q34414748-60A85E36-A16D-437A-A942-A0DB4DFEB6F9Q35690364-AA85E48C-09F9-4C7F-9587-752B31C04BDFQ36422630-F1B0FC6B-203D-4D2E-8FBC-3101CC263099Q36715742-95755234-0005-4CE4-BA04-4E2885C66B3CQ36763997-AAB17334-B325-41B6-882A-B2BC3756D43AQ36845387-40C48659-FC51-4EFA-AA04-1047A5E38B6AQ36968150-8687DCC3-A390-469A-B33F-4A2AD76AC67FQ37144809-8A1FCA71-16F9-40FF-8474-580809E52267Q37162872-AC8662C5-2B78-444A-BE4B-748F63BFDD4AQ37291338-5E84A469-8795-46B3-9DE5-D8FC6742FF06Q37461413-7DE31790-C645-47F4-83E9-68D0F7A60AF3Q37593094-70F12DE7-C28E-4A91-AF48-D661A339FE71Q38177344-1F308DAF-CB37-44D9-88A8-9AD898C8A82DQ39818415-7DC6AFE3-DA39-4FC8-8EC4-ED4FE4AA0AB2Q40174540-53D632FB-30A8-4798-ABBA-CE5498222E63Q41811933-5458A5B3-A17F-4361-A480-FE606B59B343Q42263681-5A9CA46C-1F55-4892-B4E4-939872D720A5Q42584480-49E41CFC-7401-49B8-8376-9573BF295AC4Q42868516-0139A666-9F51-43CB-ABAF-7F11AF7F9085Q45034218-55A830A0-27E1-4BA5-BE9D-288E1AE579ECQ46838800-740EE95F-B7F7-4F37-BF66-E142849CED58Q46932008-650E0373-142C-4748-A44C-68CF3F2637CDQ53652484-AF29756B-E91E-4ABE-9DBA-5E6D2EDA6CB9
P2860
In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@ast
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@en
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@nl
type
label
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@ast
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@en
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@nl
prefLabel
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@ast
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@en
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@nl
P2093
P2860
P356
P1476
In vitro activities of ceftobi ...... al survey of Belgian hospitals
@en
P2093
Ariane Deplano
Claire Nonhoff
Marc J Struelens
Marie Hallin
Olivier Denis
Raf De Ryck
Raymond Vanhoof
Ricardo De Mendonça
P2860
P304
P356
10.1128/AAC.00272-06
P407
P577
2006-08-01T00:00:00Z